搜索
艾伯维
ABBV添加自选
248.050USD
-0.030-0.01%
收盘 07/13, 16:00（美东）报价延迟15分钟
438.16B总市值
122.10市盈率 TTM
关于 艾伯维 公司
艾伯维为一家多元、科研驱动的生物制药领跑者，专注药物与疗法的研发、生产、商业化与销售。公司透过遍布美洲、欧洲与亚洲的生产与行销渠道，将疗法推向逾一百七十五个市场 。产品线横跨免疫学、肿瘤学、医美、神经科学、眼科护理及其他专科。免疫学覆盖风湿、皮肤与肠胃疾病；肿瘤学聚焦急性髓系、急性淋系、慢性淋系白血病及弥漫性大B细胞淋巴瘤；神经领域涵括帕金森、偏头痛、运动与精神障碍及阿兹海默；眼科护理面向慢性干眼、青光眼、老年性视网膜退化与屈光不正；医美业务提供 Botox Cosmetic、The Juvederm Collection of Fillers 等注射产品。管线中 NX-13 用于溃疡性结肠炎与克隆氏病治疗；CEL383 锁定炎症性肠病；ALIA-1758 瞄准阿兹海默患者群体。
艾伯维简介
公司代码ABBV
公司名称AbbVie Inc
上市日期Jan 02, 2013
CEOMichael (Robert A)
员工数量55000
证券类型Ordinary Share
年结日Jan 02
公司地址1 N Waukegan Rd
城市NORTH CHICAGO
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编60064
电话18479327900
网址https://www.abbvie.com/
公司代码ABBV
上市日期Jan 02, 2013
CEOMichael (Robert A)
艾伯维公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
45.96K
+2.43%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
39.58K
+2.82%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
30.08K
+3.72%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
17.62K
+6.35%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-346.66%
Mr. Thomas J. (Tom) Falk
Mr. Thomas J. (Tom) Falk
Independent Director
Independent Director
5.32K
+21.01%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
45.96K
+2.43%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
39.58K
+2.82%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
常见问题
艾伯维的前五大股东是谁？
艾伯维 的前五大股东如下：Dr. Azita Saleki-Gerhardt, Ph.D.
有多少机构持有艾伯维(ABBV)的股份？
截至2026Q1，共有5703家机构持有艾伯维的股份，合计持有的股份价值约为1.36B，占公司总股份的77.09%。与2025Q4相比，机构持股有所增加，增幅为26641628.00。
哪个业务部门对艾伯维的收入贡献最大？
在2026Q1，Immunology-SKYRIZI业务部门对艾伯维的收入贡献最大，创收17.56B，占总收入的28.71%。